This section synthesizes immunomodulatory strategies that (i) recalibrate the gut–liver axis and innate sensing in ALD–corticosteroids for sAH; epithelial‐targeted IL‐22/F‐652 to restore barrier defenses (Akkermansia, Reg3γ, α‐defensins) and limit endotoxemia; CRIg‐based augmentation of bacterial clearance; and IL‐1β blockade for β‐glucan/CLEC7A‐driven inflammation and (ii) reprogram macrophage polarization in MASLD, including inhibition of macrophage 17β‐HSD7 with nilotinib and dampening STING signaling via the RNF13–TRIM29 axis. The gene discussed is STING1; the disease is metabolic dysfunction-associated steatotic liver disease.